Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(31 sites)
Belgium
GSK Investigational Site, Brussels GSK Investigational Site, Ghent GSK Investigational Site, Leuven GSK Investigational Site, Liège France
GSK Investigational Site, Bordeaux